Advertisement

Animal Models of Ischemia

  • Justin A. Zivin
Part of the Advances in Neuroprotection book series (volume 22)

Abstract

There is no generally accepted specific therapy for most types of focal strokes. A major problem in rational development of therapies has been the difficulty determining whether a proposed therapy is effective. Appropriate studies in patients are complex, and few animal models are adequate for realistic and efficient tests of pharmacologic methods to reduce damage or restore neurologic function. Most cerebral stroke models have not been designed to detect whether therapy reduces neurologic injury but are intended to mimic the clinical and pathologic features of human strokes. For pharmacologic trials, a method of producing incremental grades of destruction is desirable and this is difficult to achieve with most focal stroke models. Also, regardless of the species, the infarcts vary unpredictably in size and distribution (Molinari and Laurent, 1976; Yatsu, 1976; Waltz, 1979). This degree of variability makes therapeutic trials expensive because many subjects are required. Similarly, biochemical analysis is hampered by the inability to predict the precise locations of lesions, and the marked biochemical heterogeneity of the brain complicates interpretation of the results. Since no single technique is optimal for all types of investigations, we have developed a series of stroke models that we use in a coordinated fashion for biochemical and pharmacologic studies of focal ischemia.

Keywords

Spinal Cord Neurologic Function Focal Cerebral Ischemia Cresyl Violet Stroke Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beley A, Edvinsson L, Hardebo JE (1981): Cerebral microembolization in the rat: Changes in blood-brain barrier permeability and cerebral blood flow as related to the degree of ischemia. Acta Neurol Scand 64: 88–100CrossRefGoogle Scholar
  2. Bralet J, Beley P, Jemaa R, Bralet A-M, Beley A (1987): Lipid metabolism, cerebral metabolic rate, and some related enzyme activities after brain infarction in rats. Stroke 18: 418–425CrossRefGoogle Scholar
  3. Crowell RM, Marcoux FW, DeGirolami U (1981): Variability and reversibility of focal cerebral ischemia in unanesthetized monkeys. Neurology 31: 1295–1302CrossRefGoogle Scholar
  4. DeGirolami U, Zivin JA (1982): Neuropathology of experimental spinal cord ischemia in the rabbit. J Neuropathol 41: 129–149CrossRefGoogle Scholar
  5. Faden Al, Jacobs TP (1985): Opiate antagonist WIN 44, 441–3 stereospecifically improves neurologic recovery after ischemic spinal injury. Neurology 35: 1311–1315CrossRefGoogle Scholar
  6. Finney DJ (1952): Statistical Method in Biological Assay. London: Charles GriffinGoogle Scholar
  7. Fisher RA (1922): On the mathematical foundations of theoretical statistics. Philos Trans R Soc Lond A 222: 309–368CrossRefGoogle Scholar
  8. Jacobs TP, Shohami E, Baze W, Burgard E, Gunderson C, Hallenbeck JM, Feuerstein G (1987): Deteriorating stroke model: Histopathology, edema, and eicosanoid changes following spinal cord ischemia in rabbits. Stroke 18: 741–750CrossRefGoogle Scholar
  9. Kety SS (1951): Theory and applications of the exchange of inert gas at the lungs and tissues. Pharmacol Rev 3: 4–41Google Scholar
  10. Kochhar A, Zivin JA, Lyden PD, Mazzarella V (1988): Glutamate antagonist therapy reduces neurological deficits produced by focal central nervous system ischemia. Arch Neurol 45: 148–153CrossRefGoogle Scholar
  11. Kogure K, Busto R, Scheinberg P, Reinmuth OM (1974): Energy metabolites and water content in rat brain during the early stage of development of cerebral infarction. Brain 97: 103–114CrossRefGoogle Scholar
  12. Lyden PD, Zivin JA, Kochhar A, Mazzarella V (1988): The effects of calcium channel blockers on neurological outcome following reversible and irreversible focal ischemia. Stroke 19: 1020–1026CrossRefGoogle Scholar
  13. Molinari GF, Laurent JP (1976): A classification of experimental models of brain ischemia. Stroke 7: 14–17CrossRefGoogle Scholar
  14. Palkovits M (1973): Isolated removal of hypothalamic or other brain nuclei of the rat. Brain Res 59: 449–450CrossRefGoogle Scholar
  15. Waltz AG (1979): Clinical relevance of models of cerebral ischemia. Stroke 10: 211–213CrossRefGoogle Scholar
  16. Waud DR (1972): On biological assays involving quantal responses. J Pharmacol Exp Ther 183: 577–607Google Scholar
  17. Yaksh TL, Rudy TA (1976): Chronic catheterization of the spinal subarachnoid space. Physiol Behav 17: 1031–1036CrossRefGoogle Scholar
  18. Yatsu FM (1976): Biochemical mechanisms of ischemic brain infarction. In: Handbook of Clinical Neurology, Vinken PJ, Bruyn GW, eds. New York: American ElsevierGoogle Scholar
  19. Yum SW, Faden Al (1990): Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia. Arch Neurol 47: 277–281CrossRefGoogle Scholar
  20. Zivin JA, Reid JL, Saavedra J, Kopin IJ (1975): Quantitative localization of biogenic amines in the spinal cord. Brain Res 99: 293–301CrossRefGoogle Scholar
  21. Zivin JA, DeGirolami U (1980): Spinal cord infarction: A highly reproducible stroke model. Stroke 11: 200–202CrossRefGoogle Scholar
  22. Zivin JA, DeGirolami U, Hurwitz EL (1982): Spectrum of neurological deficits in experimental CNS ischemia. Arch Neurol 39: 408–412CrossRefGoogle Scholar
  23. Zivin JA, Stashak JA (1983): The effect of ischemia on biogenic amine concentrations in the central nervous system. Stroke 14: 556–562CrossRefGoogle Scholar
  24. Zivin JA, Waud DR (1983): A precise and sensitive method for measurement of spinal cord blood flow. Brain Res 258: 197–200CrossRefGoogle Scholar
  25. Zivin JA, Venditto JA (1984): Experimental CNS ischemia: Serotonin antagonists reduce or prevent damage. Neurology 349: 469–474CrossRefGoogle Scholar
  26. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA (1985): Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230: 1289–1292CrossRefGoogle Scholar
  27. Zivin JA, DeGirolami U, Kochhar A, Lyden PD, Mazzarella V, Hemenway CC, Henry ME (1987): A model for quantitative evaluation of embolic stroke therapy. Brain Res 435: 305–309CrossRefGoogle Scholar
  28. Zivin JA, Lyden PD, DeGirolami U, Kochhar A, Mazzarella V, Hemenway CC, Johnston P (1988): Tissue plasminogen activator: Reduction of neurologic damage after experimental embolic stroke. Arch Neurol 45: 387–391CrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1992

Authors and Affiliations

  • Justin A. Zivin

There are no affiliations available

Personalised recommendations